Connor, Clark & Lunn Investment Management (CC&L)’s Gossamer Bio GOSS Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio GOSS Stock Details GOSS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$216K	Buy	658,221 +130,168	+25%	+$205K	﹤0.01%	1475
2025 Q4	$1.64M	Buy	528,053 +502,604	+1,975%	+$1.43M	﹤0.01%	985
2025 Q3	$66.9K	Buy	+25,449	New	+$56.1K	﹤0.01%	1467
2023 Q3	–	Sell	-126,233	Closed	-$151K	–	1424
2023 Q2	$151K	Sell	126,233 -139,411	-52%	-$174K	﹤0.01%	1220
2023 Q1	$335K	Buy	+265,644	New	+$508K	﹤0.01%	987
2022 Q4	–	Sell	-121,546	Closed	-$1.46M	–	1299
2022 Q3	$1.46M	Buy	121,546 +64,179	+112%	+$797K	0.01%	568
2022 Q2	$480K	Buy	57,367 +12,113	+27%	+$93.9K	﹤0.01%	792
2022 Q1	$393K	Sell	45,254 -465	-1%	-$4.48K	﹤0.01%	825
2021 Q4	$517K	Sell	45,719 -787	-2%	-$9.35K	﹤0.01%	793
2021 Q3	$585K	Buy	+46,506	New	+$428K	﹤0.01%	742

Other funds holding GOSS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KCM

Kalehua Capital Management Dallas, Texas $141M AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AVM

Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s GOSS Position: Q1 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Gossamer Bio (GOSS) stake by 25% in Q1 2026, buying an estimated $205K and bringing the position to 658,221 shares worth $216K. The position accounts for ﹤0.01% of the portfolio, ranked #1475.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in GOSS in Q3 2021 and has held it in 10 quarters since. The position peaked at $1.64M in Q4 2025. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

Connor, Clark & Lunn Investment Management (CC&L) held 658,221 shares of Gossamer Bio worth $216K as of Q1 2026.
Connor, Clark & Lunn Investment Management (CC&L) bought 130,168 Gossamer Bio shares in Q1 2026, an estimated $205K.
Gossamer Bio made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q1 2026, its #1475 holding.
Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Gossamer Bio in Q3 2021 and has held it in 10 quarters since.
Connor, Clark & Lunn Investment Management (CC&L)'s Gossamer Bio position peaked at $1.64M in Q4 2025.
184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q1 2026, filed 11 May 2026.